Hims & Hers Health stock has delivered a very large 3 year gain of about 312.5%, yet the broader valuation checks now point to a mixed picture rather than a clear bargain or clear overvaluation.

• Over the past 3 years, the share price has risen roughly 312.5%, which puts a heavy focus on whether that past return is backed by durable fundamentals.
• The launch of an AI driven Hers app for weight loss support can help support growth expectations, while the ongoing Federal Trade Commission lawsuit over data sharing and subscription practices may weigh on how investors price in future risks and potential costs.
• Hims & Hers Health screens as undervalued on several multiples, yet it only passes 4 of 6 valuation checks. The overall score of 4 out of 6 therefore still signals a mixed valuation story.

The issue now is whether the current share price of Hims & Hers Health still leaves enough valuation support after that strong multi year run and the rising regulatory overhang.

Is Hims & Hers Health Still Cheap on Sales?

P/S is a useful lens for Hims & Hers Health because investors are focused on the scale of its telehealth revenue rather than current earnings. The stock trades on a P/S of about 2.9x, compared with a Healthcare industry average of around 1.4x and a peer group around 4.3x. That puts Hims & Hers Health at a premium to the broader sector but at a discount to more closely comparable peers.

The fair P/S ratio from the model is 8.7x, which is materially above the current 2.9x level. This indicates a difference between the market price and what the model implies for a business with its growth profile, margins, size and risk factors. Despite the recent Federal Trade Commission lawsuit adding a clear regulatory overhang, the P/S multiple still suggests that the shares are trading at a discount versus this tailored benchmark.

On the preferred P/S multiple, Hims & Hers Health stock currently appears undervalued relative to the level implied by the fair ratio model.

The Hims & Hers Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Hims & Hers Health pick up where the valuation puzzle leaves off and explain what kind of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price. Each Narrative links a fair value estimate to a specific storyline about Hims & Hers Health's possible catalysts and risks so you can track which version of events appears closer to reality over time.

Community views on Hims & Hers Health sit far apart, with one side seeing a multi year growth runway and the other focused on execution and margin risk.

Bull case: 83% undervalued

"Latest news of investments (Ohio facility expansion), acquisitions (YourBio, Livewell, GRAIL Inc. stake, Eucalyptus) and category expansion (Hims TRT, Hers Menopause, Labs) reflects high confidence in demand for new offerings..."

Bear case: roughly fairly valued

"Heavy dependence on growth segments and international expansion exposes the company to regulatory, operational, and margin risks, potentially resulting in revenue volatility and compressed profitability..."

Do you think there's more to the story for Hims & Hers Health? Head over to our Community to see what others are saying!

The Bottom Line

Hims & Hers Health screens as undervalued on its preferred market multiples, yet the mixed valuation checks suggest the signal is not straightforward. After a very strong 3 year move and a live Federal Trade Commission lawsuit, the key question is whether the current discount reflects undue caution or a fair price for those risks. The core issue for investors is whether Hims & Hers Health can sustain growth and improve profitability without regulators or execution issues forcing a rethink of those valuation assumptions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.